Fda grants accelerated approval to first targeted treatment for rare dmd mutation

Fda grants accelerated approval to first targeted treatment for rare duchenne muscular dystrophy mutation.fda - approval of vyondys 53 was granted to sarepta therapeutics of cambridge, massachusetts.fda - as part of accelerated approval process, fda requires sarepta therapeutics to conduct clinical trial to confirm vyondys 53's clinical benefit.fda - if sarepta's trial fails to verify clinical benefit, fda may initiate proceedings to withdraw approval of vyondys 53's clinical benefit.
SRPT Ratings Summary
SRPT Quant Ranking